Theresa Heggie, Director at BIOCRYST PHARMACEUTICALS INC (BCRX), bought 5,000 shares at $1.45 ($7K) on 2019-11-18, disclosed to the SEC on 2019-11-18.
Open-market purchase of $7k BCRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.
| Filing → |
| BCRX | SELL | 2024-06-14 | $41K | — | Filing → |